What is Tirzepatide?
Tirzepatide is the first dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors to be FDA approved. Developed by Eli Lilly under the brands Mounjaro (type 2 diabetes) and Zepbound (obesity), it represents a new pharmacological class called “twincretin” — a molecule that simultaneously mimics two intestinal hormones.
Why the dual mechanism matters
GIP and GLP-1 receptors are complementary:
- GLP-1R: Reduces appetite, slows gastric emptying, stimulates glucose-dependent insulin secretion.
- GIPR: Improves insulin sensitivity in adipose tissue, reduces metabolic inflammation, and in combination with GLP-1, produces weight loss synergism that surpasses activation of either receptor alone.
This dual agonism is why tirzepatide produces greater weight loss than semaglutide in head-to-head comparisons.
Clinical results
SURMOUNT-1 (NEJM, 2022): Weight loss of 20.9% at 72 weeks with 15 mg/week vs. 3.1% with placebo — the greatest weight loss documented for a non-surgical drug at that time.
SURPASS-2 (head-to-head with semaglutide 1 mg): Tirzepatide 15 mg produced 12.4 kg additional weight loss vs. semaglutide.
Dose escalation (approved protocol)
| Weeks | Weekly dose |
|---|---|
| 1–4 | 2.5 mg |
| 5–8 | 5 mg |
| 9–12 | 7.5 mg |
| 13–16 | 10 mg |
| 17–20 | 12.5 mg |
| 21+ | 15 mg (maximum dose) |
Adverse effects
Similar to semaglutide’s profile: nausea (31–45%), diarrhea (17–30%), vomiting (9–23%), constipation. Generally mild to moderate and decrease after the initial escalation.
Contraindications: personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Tirzepatide vs. Semaglutide
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP+GLP-1 | GLP-1 only |
| Average weight loss | ~20% (15 mg) | ~15% (2.4 mg) |
| Frequency | Weekly | Weekly |
| Half-life | ~5 days | ~7 days |
| Obesity approval | Yes (Zepbound) | Yes (Wegovy) |
Requires a medical prescription. This content is educational. Approved tirzepatide is administered under medical supervision.
Reported protocol (research reference)
| Vial sizes | 5 mg, 10 mg, 15 mg |
|---|---|
| Reported dose | Approved protocol: start at 2.5 mg/week for 4 weeks, escalating by 2.5 mg every 4 weeks to a maintenance dose of 5–15 mg/week. Always under medical supervision. |
| Half-life | Approximately 5 days — weekly dosing. |
| FDA status | FDA approved |